Targeting a specific protein signaling pathway to treat fibrolamellar carcinoma
Targeting PLK1 signaling for the treatment of fibrolamellar carcinoma
This study is looking at a rare type of liver cancer called fibrolamellar carcinoma, mainly in kids and young adults, to find out how it grows and to discover new ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10874571 on NIH RePORTER |
What this research studies
This research focuses on fibrolamellar carcinoma (FLC), a rare and aggressive liver cancer primarily affecting children and young adults. The project aims to understand the molecular mechanisms driving FLC by investigating a unique protein fusion that contributes to tumor growth. Researchers will utilize innovative model systems, including patient-derived cell lines and xenograft mice, to identify potential therapeutic targets and develop new treatment strategies. By applying a systems-based approach, the study seeks to uncover druggable signaling networks that could lead to effective therapies for FLC.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with fibrolamellar carcinoma.
Not a fit: Patients with other types of liver cancer or those who do not have fibrolamellar carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for patients with fibrolamellar carcinoma.
How similar studies have performed: While research on fibrolamellar carcinoma is limited, similar approaches targeting specific molecular pathways in other cancers have shown promising results.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Gujral, Taran Singh — Fred Hutchinson Cancer Center
- Study coordinator: Gujral, Taran Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.